Connor, Clark & Lunn Investment Management »

Inozyme Pharma shares owned by Connor, Clark & Lunn Investment Management

Quarter-by-quarter ownership of Inozyme Pharma (INZY) shares owned by Connor, Clark & Lunn Investment Management from 13F filings

Historical chart of Connor, Clark & Lunn Investment Management investment in Inozyme Pharma

Tip: Access up to 7 years of quarterly data

All positions including Inozyme Pharma held by Connor, Clark & Lunn Investment Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Inozyme Pharma by Connor, Clark & Lunn Investment Management

Quarter filed Position value Share count Share price at filing
2024-03-31 $267k 35k 7.66

More positions owned by Connor, Clark & Lunn Investment Management

Rbc Cad (RY)
Microsoft Corporation (MSFT)
Apple (AAPL)
Toronto Dominion Bk Ont Com New (TD)
NVIDIA Corporation (NVDA)
Bk Nova Cad (BNS)
Canadian Natl Ry (CNI)
Cibc Cad (CM)
Canadian Natural Resources (CNQ)
Amazon (AMZN)
Thomson Reuters Corp. (TRI)
Shopify Cl A (SHOP)
Canadian Pacific Kansas City (CP)
Enbridge (ENB)
Manulife Finl Corp (MFC)

View all positions for Connor, Clark & Lunn Investment Management

Top funds holding Inozyme Pharma

Adage Capital Partners GP
Pivotal bioVenture Partners Investment Advisor
Sofinnova Ventures
Eventide Asset Management
Rock Springs Capital Management
Samlyn Capital
BlackRock
Affinity Asset Advisors
Vanguard Group
NEA Management Company
FMR
Millennium Management
Samsara BioCapital
Sphera Funds Management
Geode Capital Management

View all funds holding Inozyme Pharma